CT
CTSO.US Cytosorbents Crp
- Market cap
- USD 15.3M
- P/E
- -
- P/B
- 11.43x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CTSO.US undervalued?
Graham numberThe Graham number of Cytosorbents Crp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cytosorbents Crp fundamental analysis
No fundamental analysis for Cytosorbents Crp yet.
Cytosorbents Crp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery …
Full company profileCytosorbents Crp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cytosorbents Crp annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.21M | 13.4M | 20.3M | 22.8M | 39.5M | 40.1M | 34.7M | 31.1M | 35.6M | 37.1M | 37.6M |
| Gross Profit | 4.25M | 7.86M | 12.8M | 15.4M | 28.4M | 29.1M | 20.7M | 22.0M | 24.9M | 26.5M | 27.3M |
| Operating Income | -11.5M | -9.84M | -15.6M | -19.0M | -10.4M | -22.7M | -31.5M | -31.9M | -16.5M | -14.2M | -9.13M |
| EBITDA | -11.9M | -8.17M | -16.0M | -18.4M | -9.71M | -24.2M | -29.8M | -27.9M | -19.3M | -4.36M | -10.2M |
| Net Income | -11.9M | -8.46M | -17.2M | -19.3M | -7.84M | -24.6M | -32.8M | -29.2M | -20.7M | -8.20M | -15.2M |
| EPS | -9.39 | -6.13 | -0.56 | -12 | -4.04 | -11 | -15 | -13 | -7.61 | -2.63 | -4.82 |
| Balance Sheet | |||||||||||
| Total Assets | 9.69M | 24.1M | 32.7M | 27.4M | 90.0M | 89.5M | 63.2M | 53.3M | 47.4M | 44.2M | 37.2M |
| Total Liabilities | 10.2M | 13.8M | 15.8M | 24.0M | 10.7M | 26.9M | 27.9M | 30.0M | 36.3M | 38.3M | 39.5M |
| Shareholders' Equity | -474K | 10.3M | 16.9M | 3.42M | 79.2M | 62.6M | 35.4M | 23.3M | 11.1M | 5.90M | -2.31M |
| Cash & Short-term Investments | 5.25M | 17.3M | 22.4M | 12.2M | 71.4M | 52.1M | 22.1M | 14.1M | 3.28M | 6.25M | 4.21M |
| Total Debt | 4.91M | 9.99M | 9.94M | 16.6M | 1.03M | 13.8M | 18.3M | 18.3M | 26.9M | 29.1M | 29.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.73M | -6.46M | -10.8M | -16.8M | -5.61M | -14.0M | -28.2M | -21.7M | -14.4M | -12.4M | -4.23M |
| Capital Expenditure | 596K | 1.68M | 1.52M | 1.52M | 1.68M | 4.28M | 6.46M | 936K | 284K | 164K | 74.7K |
| Free Cash Flow | -7.33M | -8.14M | -12.4M | -18.3M | -7.29M | -18.3M | -34.7M | -22.6M | -14.7M | -12.5M | -4.31M |
| Ratios | |||||||||||
| ROE | - | -82.4% | -101.6% | -563.7% | -9.9% | -39.2% | -92.8% | -125.7% | -186.5% | -138.9% | - |
| ROA | -123.2% | -35.1% | -52.6% | -70.4% | -8.7% | -27.4% | -51.9% | -54.9% | -43.7% | -18.6% | -40.8% |
| Net Profit Margin | -145.5% | -63.2% | -85.0% | -84.6% | -19.9% | -61.2% | -94.6% | -94.1% | -58.2% | -22.1% | -40.3% |
| Debt to Equity | - | 0.97x | 0.59x | 4.84x | 0.01x | 0.22x | 0.52x | 0.79x | 2.42x | 4.93x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cytosorbents Crp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 5.00M | 2.29 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 336K | 0.24 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Sep 8, 2026.
Who owns Cytosorbents Crp
- Insiders 16.25%
- Institutions 21.82%
- Public & others 61.93%
- Shares outstanding 3.15M
- Free float 2.77M
Top funds holding CTSO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Neuberger US Sm Cp Intrs Val USD I Acc | 88.7K | 0.14% | 0.00% | Jul 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 63.7K | 2.02% | 0.00% | Sep 2026 |
| Neuberger Intrinsic Value I | 32.3K | 1.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 22.2K | 0.04% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 14.5K | 0.46% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 4.72K | 0.15% | -0.02% | Sep 2026 |
| Fidelity Series Total Market Index | 3.93K | 0.12% | -0.03% | Sep 2026 |
| Vanguard Balanced Index Inv | 1.78K | 0.06% | 0.00% | Sep 2026 |
| Morgan Stanley Pathway Sm-Md Cp Eq ETF | 1.03K | 0.03% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 694.00 | 0.02% | +0.14% | Sep 2026 |
| Guggenheim Active Allocation Fund | 490.00 | 0.00% | 0.00% | Aug 2026 |
| Column Small Cap Select | 338.00 | 0.01% | +0.30% | Sep 2026 |
| Column Small Cap | 91.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding CTSO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Avenir Corporation | 5.19M | 8.23% | -0.51% | Jun 2026 |
| Neuberger Berman Group LLC | 1.97M | 3.12% | +16.97% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.91M | 3.04% | +1.81% | Jun 2026 |
| CM Management, LLC | 1.48M | 2.34% | 0.00% | Jun 2026 |
| BlackRock Inc | 627K | 1.00% | -19.90% | Jun 2026 |
| Geode Capital Management, LLC | 602K | 0.96% | -14.87% | Jun 2026 |
| Sargent Investment Group, LLC | 556K | 0.88% | +1.07% | Jun 2026 |
| Pathstone Holdings LLC | 500K | 0.79% | -0.01% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 316K | 0.50% | +0.74% | Jun 2026 |
| CIBC Bancorp USA Inc. | 173K | 0.27% | 0.00% | Jun 2026 |
| State Street Corp | 159K | 0.25% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 135K | 0.21% | +3.39% | Jun 2026 |
| UBS Group AG | 131K | 0.21% | +13.73% | Jun 2026 |
| Northern Trust Corp | 112K | 0.18% | +20.66% | Jun 2026 |
| Nwf Advisory Services Inc | 104K | 0.17% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 100K | 0.16% | -0.70% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 91.3K | 0.14% | -8.82% | Jun 2026 |
| Virtu Financial LLC | 71.5K | 0.11% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 54.3K | 0.09% | +52.70% | Jun 2026 |
| Jane Street Group LLC | 52.2K | 0.08% | 0.00% | Jun 2026 |
Cytosorbents Crp company profile
- Company name
- Cytosorbents Crp
- Ticker
- CTSO.US
- Exchange
- USA Stocks
- Listed since
- Nov 7, 2013
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 129
- Fiscal year end
- December
- Address
- 305 College Road East, Princeton, NJ, United States, 08540
- Phone
- 732 329 8885
- Website
- cytosorbents.com
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Cytosorbents Crp management
9- Dr. Phillip P. Chan M.D., Ph.D.CEO & Director · born 1970
- Mr. Vincent J. Capponi M.S.President & COO · born 1958
- Mr. Peter J. Mariani CPAChief Financial Officer · born 1964
- Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.Chief Medical Officer · born 1969
- Dr. Christian Steiner M.D.Executive Vice President of Sales & Marketing
- Mr. Christopher Cramer M.B.A., M.S.Senior Vice President of Business Development
- Ms. Kathleen P. Bloch CPA, M.B.A.Advisor · born 1955
- Jodi HooverExecutive
- Dr. Robert H. Bartlett M.D.Co-Chairman of Cardiac Surgery Advisory Board & Consultant · born 1939